S1P agonists such as fingolimod and the recently FDA approved drug, ozanimod, have been reported to result in significant amelioration in the severity of MS and EAE, mainly attributed to interfering with infiltration of activated autoreactive T lymphocytes expressing S1PR1 into the CNS (12, 13). This evidence concerns the gene S1PR1 and myeloid sarcoma.